IDiyas

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Michele Potashman

USPTO Granted Patents = 13 

 

 

Average Co-Inventor Count = 11.6

ph-index = 7

Forward Citations = 134(Granted Patents)


Company Filing History:

goldMedal13 out of 1,970 
 
Amgen Inc.
 patents

Years Active: 2008-2019

where 'Filed Patents' based on already Granted Patents

13 patents (USPTO):
1. 10344041 - Polymorphic forms and co-crystals of a c-Met inhibitor (2019-07-09),
2. 9981988 - Polymorphic forms and co-crystals of a c-Met inhibitor (2018-05-29),
3. 9115127 - Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase (2015-08-25),
4. 9066954 - Fused heterocyclic derivatives and methods of use (2015-06-30),
5. 8716281 - Pyrimidine compounds that inhibit anaplastic lymphoma kinase (2014-05-06),
6. 8685983 - Method of treating cancer with substituted amide derivatives (2014-04-01),
7. 8524900 - Fused heterocyclic derivatives and methods of use (2013-09-03),
8. 8217177 - Fused heterocyclic derivatives and methods of use (2012-07-10),
9. 8178557 - Compounds and methods of use (2012-05-15),
10. 8088794 - Substituted amide derivatives and methods of use (2012-01-03),
11. 7759344 - Bis-aryl amide derivatives and methods of use (2010-07-20),
12. 7531553 - Heterocyclic compounds and methods of use (2009-05-12),
13. 7435823 - Compounds and methods of use (2008-10-14),

Title: The Innovative Mind of Michele Potashman

Introduction

Michele Potashman is a notable inventor based in Cambridge, MA, whose contributions to the field of cancer research have garnered attention. With a remarkable portfolio of 13 patents, Potashman continues to push the boundaries of scientific innovation.

Latest Patents

One of Potashman's latest inventions focuses on "Polymorphic forms and co-crystals of a c-Met inhibitor." This invention provides novel polymorphic forms and co-crystals of a compound designed for the treatment, prevention, or amelioration of cancer. Specifically, the patent presents polymorphs and co-crystals of the compound 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which serves as an effective inhibitor of c-Met in cancer therapy.

Career Highlights

Potashman is currently associated with Amgen Inc., a prominent company in biopharmaceutical innovation. His work is pivotal in advancing the pharmaceutical applications vital for various medical conditions, particularly in oncology.

Collaborations

Throughout his career, Michele has collaborated with esteemed colleagues, including Jean-Christophe P Harmange and Deborah Choquette. These collaborations have played an essential role in enhancing the development of his groundbreaking inventions in the pharmaceutical domain.

Conclusion

Michele Potashman's innovative contributions highlight the critical intersection of patent research and practical applications in cancer treatment. His dedication and collaborative efforts not only innovate existing therapies but also pave the way for future advancements in medical science. As an inventor committed to improving health outcomes, Potashman's work stands as a testament to the power of innovation in addressing complex challenges in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…